Drug General Information
Drug ID
D00DHM
Former ID
DIB015188
Drug Name
SDZ-208911
Synonyms
SDZ-HAC-911; N-[(8alpha)-2,6-Dimethylergolin-8-yl]-2,2-dimethylpropanamide; N-(5,7-Dimethyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[4,3-fg]quinolin-9alpha-yl)-2,2-dimethylpropanamide; 2,6-Dimethyl-8alpha-(2,2-dimethyl-1-oxopropylamino)ergoline
Drug Type
Small molecular drug
Indication Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] Investigative [528305], [551871]
Structure
Download
2D MOL

3D MOL

Formula
C21H29N3O
Canonical SMILES
CC1=C2CC3C(CC(CN3C)NC(=O)C(C)(C)C)C4=C2C(=CC=C4)N1
InChI
1S/C21H29N3O/c1-12-15-10-18-16(14-7-6-8-17(22-12)19(14)15)9-13(11-24(18)5)23-20(25)21(2,3)4/h6-8,13,16,18,22H,9-11H2,1-5H3,(H,23,25)
InChIKey
ZNMWUMGOSWLWOH-UHFFFAOYSA-N
CAS Number
CAS 101000-37-7
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Modulator [528305], [551871]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 528305Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 528305Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.